LA JOLLA, Calif., Dec. 16 /PRNewswire/ -- At its Annual Meeting of
Shareholders today, Agouron Pharmaceuticals, Inc., (Nasdaq: AGPH) reported
that its shareholders approved the company's Divisional Stock Proposal and
other related proposals. The Divisional Stock Proposal received the
affirmative vote of the holders of a majority of all outstanding shares of
Agouron common stock. As a result, Agouron's Board of Directors is authorized
to create divisional securities separately tracking the performance of its
oncology operations and its non-oncology operations.
Agouron Pharmaceuticals, Inc. is an integrated pharmaceutical company
committed to the discovery, development, manufacturing, and marketing of
innovative therapeutic products engineered to inactivate proteins that play
key roles in cancer, AIDS, and other serious diseases.
SOURCE Agouron Pharmaceuticals, Inc.
 back to top
Related links:
http://www.agouron.com
Company News On-Call:
http://www.prnewswire.com/comp/019650.html or fax,
800-758-5804, ext. 019650
CONTACT:
Donna Nichols, Vice President, Head of
Corporate Communications of Agouron Pharmaceuticals, Inc.,
619-622-3009
|
